

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN BLISIBIMOD
PRONUNCIATION blye sib' i mod
THERAPEUTIC CLAIM Autoimmune diseases

CHEMICAL NAMES

1. Protein (synthetic cytokine BAFF-binding domain fragment) fusion protein with immunoglobulin G1 (human Fc fragment), dimer
2. Glycyl-L-cysteinyl-L-lysyl-L-tryptophyl-{{29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)}]human tumor necrosis factor receptor superfamily member 13C (BAFF receptor, CD268)-(26-31)-peptidyl}-L-tryptophyl-L-valyl-L-cysteinyl-L-aspartyl-L-prolyl-L-leucylglycyl-L-serylglycyl-L-seryl-L-alanyl-L-threonylglycylglycyl-L-serylglycyl-L-seryl-L-threonyl-L-alanyl-L-seryl-L-serylglycyl-L-serylglycyl-L-seryl-L-alanyl-L-threonyl-L-histidyl-L-methionyl-L-leucyl-L-prolylglycyl-L-cysteinyl-L-lysyl-L-tryptophyl-{{29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)}]human tumor necrosis factor receptor superfamily member 13C (BAFF receptor, CD268)-(26-31)-peptidyl}-L-tryptophyl-L-valyl-L-cysteinyl-L-aspartyl-L-prolyl-L-leucylpentaglycyl-L-valyl-(human immunoglobulin heavy constant gamma 1 Fc-(6-232)-peptide) dimer (69-69':72-72')-bisdisulfide

STRUCTURAL FORMULA

Monomer sequence

GCKWDLLIKQ	WVCDPLGSGS	ATGGSGSTAS	SGSGSATHML	PGCKWDLLIK	50
QWVCDPLGGG	GGVDKTHTCP	PCPAPELLGG	PSVFLFPPKP	KDTLMISRTP	100
EVTVCVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	STYRVVSVLT	150
VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	VYTLPPSRDE	200
LTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTPPV	LDSGDSFFLY	250
SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK		290

Disulfide bridges

2-13 2'-13' 43-54 43'-54' 69-69' 72-72' 104-164 104'-164' 210-268 210'-268'

MOLECULAR FORMULA $C_{2836}H_{4376}N_{756}O_{858}S_{26}$

MOLECULAR WEIGHT 63.62 kDa

TRADEMARK None as yet

SPONSOR Anthera Pharmaceuticals, Inc.

CODE DESIGNATION A-623

CAS REGISTRY NUMBER 1236126-45-6